Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium adjunctive therapy for stroke-associated pneumonia after intracerebral hemorrhage
ChiCTR2600121962Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in intracerebral hemorrhage (ICH) and pneumonia comparing Intervention Group (sivelestat sodium) with Control Group (placebo) (2 arms). Primary endpoint: Incidence of stroke-associated pneumonia within 7 days after admission. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
intracerebral hemorrhage (ICH)pneumonia
Beyond the preview
Go deeper on ChiCTR2600121962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121962.